Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ashitaba Powder Increases Bone Mass in Osteoporotic Rats: Takara Bio
July 17, 2006
- Taiho Licenses TS-1 to sanofi-aventis
July 17, 2006
- New Series：Drug Development Beyond Boundaries -Today's Global Cooperative Clinical Trials- Part I: Overview
July 17, 2006
- Generics Should Use Only Generic Name: Prof. Matsuyama
July 10, 2006
- SEMINAR
July 10, 2006
- Generic Marketing Companies Asked to Cooperate in Follow-up Market Price Surveys
July 10, 2006
- Bayer to Sell Diagnostics Business to Siemens
July 10, 2006
- TOPIC an article
July 10, 2006
- MEDICAL DEVICES/DIAGNOSTICS NEWS IN BRIEF
July 10, 2006
- METI Proposes "Economic Growth Strategy Framework"
July 10, 2006
- NEW PRODUCTS
July 10, 2006
- Council Proposes Cuts of \11.4-14.3 Tril. Over Next 5 Years
July 10, 2006
- SEMINAR
July 10, 2006
- Otsuka's Mozavaptan Recommended for Approval
July 10, 2006
- Asahi Kasei Licenses Fasudil to CoTherix
July 10, 2006
- Proposed Vision Calls For Support of Vaccine Development
July 10, 2006
- SURVEY 2 articles
July 10, 2006
- HPB Sets Up Another Study Group to Promote Clinical Trials
July 10, 2006
- Oncology Div. Preparing to Launch Nexavar: Bayer Yakuhin
July 10, 2006
- REGULATORY NEWS IN BRIEF
July 10, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…